| Income Statement | 2025-09-30 | |||
|---|---|---|---|---|
| General and administrative expenses | 3,078,378 | |||
| Research and development | 4,584,131 | |||
| Total operating expenses | 7,662,509 | |||
| Loss from operations | -7,662,509 | |||
| Interest income | 84,539 | |||
| Total other expense, net | 84,539 | |||
| Loss before provision for income taxes | -7,577,970 | |||
| Provision for income taxes | 7,722 | |||
| Net loss | -7,585,692 | |||
| Net loss attributable to immix biopharma, inc. common stockholders | -7,585,692 | |||
| Foreign currency translation | -2,568 | |||
| Total other comprehensive loss | -2,568 | |||
| Comprehensive loss | -7,588,260 | |||
| Loss per common share - basic | -0.24 | |||
| Loss per common share - diluted | -0.24 | |||
| Weighted average shares outstanding - basic | 31,926,651 | |||
| Weighted average shares outstanding - diluted | 31,926,651 | |||
Immix Biopharma, Inc. (IMMX)
Immix Biopharma, Inc. (IMMX)